肌层浸润性膀胱癌新辅助化疗后风险导向治疗的II期试验(RETAIN 1)
该项单臂II期非劣效性试验纳入70例cT2-T3N0M0肌层浸润性膀胱癌患者,接受AMVAC方案新辅助化疗,根据ATM、ERCC2、FANCC、RB1突变及cT0分期决定是否进入主动监测。中位随访40个月,2年无转移生存率为72.9%,未达到主要终点,但17%患者及48%主动监测组患者避免膀胱切除术且无转移。
要点
- 70例患者中33例(47%)存在至少一个DNA损伤修复基因突变,25例(36%)进入主动监测。
- 全组2年无转移生存率为72.9%(单侧95%CI下限62.8%),未超过预设的64%下限。
- 主动监测组2年无转移生存率为76.0%,非主动监测组为71.1%。
核心结论
- 接受AMVAC新辅助化疗后风险导向局部巩固治疗的肌层浸润性膀胱癌患者2年无转移生存率为73%,主要终点未达到,但17%的入组患者和48%的主动监测组患者避免膀胱切除术且无转移。
研究设计与样本
- 单臂、II期、非劣效性试验,纳入70例cT2-T3N0M0肌层浸润性膀胱癌患者,接受AMVAC方案新辅助化疗,对新辅助化疗前经尿道膀胱肿瘤标本测序ATM、ERCC2、FANCC和RB1突变,携带至少1个突变且新辅助化疗后cT0的患者开始主动监测。
- 主要终点为全队列2年无转移生存率,若精确单侧95%CI下限超过64%则拒绝无效假设。
主要发现
- 70例患者中33例(47%)携带突变,25例(36%)按方案开始主动监测。
- 中位随访40个月,全组2年无转移生存率为72.9%(精确单侧95%CI下限62.8%)。
- 主动监测组2年无转移生存率为76.0%(95%CI 54.2至88.4),其余患者为71.1%(95%CI 55.5至82.1)。
- 主动监测组中17例(68%)出现某种复发,12例(48%)无转移且保留膀胱。
- 2年总生存率为84.3%(95%CI 73.4至91.0);主动监测组为88.0%(95%CI 67.3至96.0),非主动监测组为82.2%(95%CI 67.6至90.7)。
关键数值与推荐
- 主要终点预设无效假设为精确单侧95%CI下限不超过64%,实际全组2年无转移生存率72.9%的精确单侧95%CI下限为62.8%,未超过64%。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Cisplatin-based neoadjuvant chemotherapy (NAC) followed by cystectomy is the standard of care for patients with muscle-invasive bladder cancer (MIBC). Mutations in DNA damage repair genes are associated with pathologic downstaging after NAC. We hypothesized that a combination of biomarker selection and clinical staging would identify patients for cystectomy-sparing active surveillance (AS). PATIENTS AND METHODS: We conducted a single-arm, phase II, noninferiority trial to evaluate a risk-adapted approach for MIBC. Patients with cT2-T3N0M0 MIBC underwent NAC with accelerated methotrexate, vinblastine, doxorubicin, and cisplatin (AMVAC). Pre-NAC transurethral bladder tumor specimens were sequenced for mutations in ATM, ERCC2, FANCC, and RB1. Patients with ≥1 mutation and cT0 post-NAC began AS. The primary end point was metastasis-free survival (MFS) at 2 years for the entire cohort with the null hypothesis rejected if the lower bound exact one-sided 95% CI exceeds 64%. RESULTS: Seventy patients were enrolled, 33 (47%) had a mutation, and 25 (36%) began per-protocol AS. With a median follow-up of 40 months, the 2-year MFS for all patients was 72.9% (lower bound exact one-sided 95% CI, 62.8). The 2-year MFS was 76.0% in the AS group (95% CI, 54.2 to 88.4) and 71.1% (95% CI, 55.5 to 82.1) in the remaining patients. In the AS group, 17 patients (68%) had some recurrence and 12 (48%) were metastasis-free with an intact bladder. The 2-year overall survival (OS) was 84.3% (95% CI, 73.4 to 91.0); OS was 88.0% (95% CI, 67.3 to 96.0) and 82.2% (95% CI, 67.6 to 90.7) in the AS and not-AS groups, respectively. CONCLUSION: Patients with MIBC treated with AMVAC followed by a risk-adapted approach to local consolidation achieved a 2-year MFS rate of 73%. The primary end point was not met, but 17% of all enrolled patients and 48% of the AS group avoided cystectomy without metastatic disease.
引用
- Geynisman DM, Abbosh PH, Ross E, et al. Phase II Trial of Risk-Enabled Therapy After Neoadjuvant Chemotherapy for Muscle-Invasive Bladder Cancer (RETAIN 1). J Clin Oncol. 2024. PMID: 39680823. doi:10.1200/JCO-24-01214
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。